Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher
Crossmark

Investigation on Serum Levels of Interleukin-18 and Interleukin-6 in Patients With Dermatomyositis and Polymyositis

Samaneh Khazaei Asl 1 , Ali Shahraki 1 , * and Zahra Zakeri 2
Authors Information
1 Department of Biology, Faculty of Science, University Of Sistan and Baluchestan, Zahedan, IR Iran
2 Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Shiraz E-Medical Journal: February 01, 2016, 17 (2); e34981
  • Published Online: February 28, 2016
  • Article Type: Research Article
  • Received: November 23, 2015
  • Accepted: February 15, 2016
  • DOI: 10.17795/semj34981

To Cite: Khazaei Asl S, Shahraki A, Zakeri Z. Investigation on Serum Levels of Interleukin-18 and Interleukin-6 in Patients With Dermatomyositis and Polymyositis, Shiraz E-Med J. 2016 ; 17(2):e34981. doi: 10.17795/semj34981.

Abstract
Copyright © 2016, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011; 13(3): 225-32[DOI][PubMed]
  • 2. Rayavarapu S, Coley W, Kinder TB, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle. 2013; 3(1): 13[DOI][PubMed]
  • 3. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003; 73(2): 213-24[PubMed]
  • 4. Shahraki A, Zakeri Z, Hosseinian M, Hajnegad S. interleukin-33 and interleukin-18 serum levels in patients with rheumatoid arthritis and osteoporosis [in Persian]. J Birjand Univ Med Sci. 2014; 21(1): 86-95
  • 5. Lindegaard B, Matthews VB, Brandt C, Hojman P, Allen TL, Estevez E, et al. Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes. 2013; 62(9): 3064-74[DOI][PubMed]
  • 6. Morel JC, Park CC, Woods JM, Koch AE. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem. 2001; 276(40): 37069-75[DOI][PubMed]
  • 7. Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, et al. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther. 2011; 13(2)[DOI][PubMed]
  • 8. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14(6): 705-14[DOI]
  • 9. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci. 2012; 8(9): 1227-36[DOI][PubMed]
  • 10. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000; 6(5): 583-8[DOI][PubMed]
  • 11. Morales-Montor J. The role of the pleiotropic cytokine interleukin-6 (IL-6) during disease. Mod Asp Immunobiol. 2005; 16: 21-6
  • 12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7): 344-7[DOI][PubMed]
  • 13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8): 403-7[DOI][PubMed]
  • 14. Shimojima Y, Ishii W, Matsuda M, Ikeda SI. Phenotypes of peripheral blood lymphocytes and cytokine expression in polymyositis and dermatomyositis before treatment and after clinical remission. Cli Med Insights: Arthritis and musculoskeletal disorders. 2012; 5: 77-87
  • 15. Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014; 53(3): 397-405[DOI][PubMed]
  • 16. De Paepe B, Zschuntzsch J. Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies. Int J Mol Sci. 2015; 16(8): 18683-713[DOI][PubMed]
  • 17. Gono T, Kawaguchi Y, Sugiura T, Ichida H, Takagi K, Katsumata Y, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010; 49(10): 1878-81[DOI][PubMed]
  • 18. Tucci M, Quatraro C, Dammacco F, Silvestris F. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp immunol. 2006; 146(1): 21-31[DOI]
  • 19. Tucci M, Quatraro C, Dammacco F, Silvestris F. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci. 2007; 1107: 184-92[DOI][PubMed]
  • 20. Kaser A, Kaser S, Kaneider NC, Enrich B, Wiedermann CJ, Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood. 2004; 103(2): 648-55[DOI][PubMed]
  • 21. Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M, et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J Immunol. 2004; 173(8): 5312-8[PubMed]
  • 22. Liew FY, Wei XQ, McInnes IB. Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis. 2003; 62 Suppl 2-50[PubMed]
  • 23. Murakami M, Hirano T. The pathological and physiological roles of IL-6 amplifier activation. Int J Biol Sci. 2012; 8(9): 1267-80[DOI][PubMed]
  • 24. Yang M, Cen X, Xie Q, Zuo C, Shi G, Yin G. Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis. Clin Dev Immunol. 2013; 2013: 717808[DOI][PubMed]
  • 25. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000; 164(12): 6593-600[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments